跳至主要内容
临床试验/NCT05938088
NCT05938088招募中不适用

Mirogabalin and Pain After Total Hip Arthroplasty: a Double-blind, Randomized, Placebo-controlled Trial

Gangnam Severance Hospital1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2023年7月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
56
试验地点
1
主要终点
numeric rating scale at flexion

研究概览

简要总结

The purpose of this study is to confirm the analgesic effect of mirogabalin in patients undergoing unilateral hip arthroplasty.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients 19 years of age or older who are expected to undergo unilateral hip arthroplasty
  • American Society of Anesthesiologists class 1-3

排除标准

  • Major prior ipsilateral open hip surgery
  • Allergies to drugs used in research
  • Difficult to manage diabetes mellitus (including insulin dependence)
  • Chronic use of gabapentin or pregabalin (regular use for more than 3 months)
  • Patients taking cimetidine, probenecid, or lorazepam
  • Patients with moderate or severe hepatic impairment (AST/ALT 2.5 times or more of the upper limit of normal)
  • Estimated glomerular filtration rate < 60 mL/min/1.73m2
  • Dependence on opioids
  • In the case of subjects who cannot read the consent form (e.g. illiterate, foreigners, etc.)

研究组 & 干预措施

placebo group

Sham Comparator

placebo

干预措施: Arm II (placebo group) (Drug)

mirogabalin group

Experimental

perioperative mirogabalin

干预措施: Arm I (mirogabalin group) (Drug)

结局指标

主要结局

numeric rating scale at flexion

时间窗: postoperative day 1

A score of 0 indicates no pain and a score of 10 indicates maximum pain.

次要结局

  • numeric rating scale at flexion(up to 3 month after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Do-Hyeong Kim

Associate Professor

Gangnam Severance Hospital

研究点 (1)

Loading locations...

相似试验